Savara faces an FDA setback for Molbreevi, its aPAP treatment. Learn how the company plans to recover and file a new BLA by ...

Lexi Homberger — a third grade teacher at Dodge Elementary — was recognized in 2023, by the Williamsville School Board, after ...

Experts say there’s no evidence GLP-1s can be absorbed through the skin — and these patches don’t contain the FDA-approved ...

George Tidmarsh, a Stanford University physician who founded Horizon Pharma and later ran La Jolla Pharma, was named head of ...

Replimune's RP1 treatment for advanced melanoma faces FDA rejection due to trial design issues, despite promising results ...

Replimune stock cratered Tuesday after the Food and Drug Administration unexpectedly rejected its experimental melanoma ...

Following a prolonged and high-stakes legal battle, the U.S. Food and Drug Administration (FDA) granted Juul marketing ...

The measure provides $27.1 billion to agencies including the USDA and FDA to invest in America’s rural communities, support ...

This latest approval builds on an earlier liquid formulation of generic methimazole for feline hyperthyroidism, which ...

A functional precision medicine platform intends to streamline cancer treatment by matching patients against a battery of FDA ...

The FDA cited trial design concerns and lack of substantial evidence in denying approval for Replimune’s biologics license application in advanced melanoma.

Vusolimogene oderparepvec is a genetically modified herpes simplex type 1 virus designed to directly destroy tumors and generate an anti-tumor immune response.